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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
Parathyroid Hormone (PTH) replacement therapy an effective treatment for patients with
hypoparathyroidism?”
STUDY DESIGN: Review of a randomized control trial published in 2011, a prospective cohort
study published in 2013, and a randomized crossover study published in 2012.
DATA SOURCES: All articles used were published in English, and were found in peer-reviewed
journals using PubMed.
OUTCOMES MEASURED: The need to remove supplemental calcium from the diet, the
amount PTH was used to maintain a normal range, and the method of PTH delivery (daily
injections vs. subcutaneous pump).
RESULTS: Sikjaer et al found that patients were able to completely eliminate their daily dose of
calcium and active vitamin D supplements without developing hypocalcemia compared to a
placebo group. Cusano et al found that patients were able to reduce supplemental calcium and
vitamin D significantly for up to four years as compared to a placebo group. Winer et al found
that patients were able to use less PTH hormone to reduce supplemental calcium and magnesium
supplementation from the diet.
CONCLUSIONS: The results of the three studies demonstrate that PTH replacement therapy is
an adequate therapy for managing patients with hypoparathyroidism. In all three studies, PTH
replacement therapy proved the maintenance of calcium levels in the blood, without
hypocalcemia or hypercalcemia effects. This ultimately allowed patients to remove the need for
supplemental calcium from the diet, or significantly reduce the amount of calcium and vitamin D
supplements from the diet.
KEY WORDS: PTH replacement, hypoparathyroidism
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INTRODUCTION
Hypoparathyroidism is a chronic endocrine disorder that occurs when there is progressive
destruction of the parathyroid glands, abnormal development, altered parathyroid hormone
(PTH) production, or impaired PTH action4. This results in hypocalcemia which has a range of
clinical manifestations ranging from fatigue, irritability, paresthesias to refractory heart failure,
laryngeal spasms, and death4.
The incidence of hypoparathyroidism most commonly occurs in about 18% of patients
after undergoing a thyroidectomy, with about 9.5% of those patients becoming symptomatic. The
risk of developing hypoparathyroidism increases with age, especially for those who undergo a
total thyroidectomy over the age of 502. A rare cause of hypoparathyroidism is autoimmune,
which can be isolated or combined with polyglandular autoimmunity type I (PGA-1). Congenital
causes of hypoparathyroidism include DiGeorge’s Syndrome where the parathyroid glands are
absent or atrophied5. Transient hypoparathyroidism can be caused by manipulation of the blood
supply or removal of one or more parathyroid glands during surgery2. Intermittent
hypoparathyroidism can be a result of parathyroid insufficiency4.
A good history and physical exam, along with adequate laboratory testing is necessary to
make the proper diagnosis of hypoparathyroidism. When serum calcium levels are decreased
(less than 8.5 mg/dL) and serum phosphorous levels are elevated (>5.4 mg/dL), patients will start
to become symptomatic, which includes fatigue, irritability, restless, and may include
paresthesias4. If picked up early enough, a PTH immunometric assay can be ordered which will
reveal a low serum PTH level. Once hypoparathyroidism is diagnosed, they are either treated as
an acute or chronic patient, depending on severity of symptoms. If the patient is acute, he or she
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is treated with IV calcium with calcitrol supplementation. If the patient is chronic, he or she will
require lifelong oral calcium with vitamin D supplementation4.
In the United States, the surgical cause of hypoparathyroidism resulted in 8,901 cases
over a 12-month period from 2007 – 2008, with 75% being transient and 25% being chronic5.
Currently, the prevalence of hypoparathyroidism in the U.S. is estimated at 60-80,000 patients5.
While there is no direct measurement of how much money is spent on managing patients with
hypoparathyroidism, the surgical cause of the disease is measured at approximately $4,6423.
Currently, PTH replacement therapy is not approved as monotherapy by the Food and
Drug Administration in the United States. Calcium and vitamin D supplementation for
hypoparathyroidism has proven to be effective but require lifelong monitoring and carry a great
number of adverse reactions not limited to hypercalcemia and kidney stones4. PTH replacement
therapy may be used as a treatment for patients with hypoparathyroidism4. Hypoparathyroidism
is the only endocrine disorder in the United States without a single hormone replacement therapy
as a treatment option4.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not, “Parathyroid
Hormone (PTH) replacement therapy is an effective treatment for patients with
hypoparathyroidism?”
METHODS
The population for this study included all patients with hypoparathyroidism. The
intervention studied was PTH (1-34) or PTH (1-84) replacement therapy. The treatment groups
of PTH replacement therapy delivered via subcutaneous injections and continuous pump therapy
were compared with placebo groups or twice daily subcutaneous injections of PTH. The

Kelly, PTH Replacement Therapy

3

outcomes measured were patient oriented evidence. They included the number of patients who
were able to remove supplemental calcium from their diet, the lowest amount of PTH necessary
for subcutaneous pump therapy to maintain normal levels of calcium in the blood, and serum
calcium and vitamin D levels in the blood. This systematic review includes a randomized control
trial, a randomized crossover study, and a prospective cohort study.
The three studies included in this review were found using PubMed database by the
author. Keywords included in the search were “PTH replacement therapy” and
“hypoparathyroidism.” All articles were published in English in peer-reviewed journals. The
three studies selected were chosen based on their relevance to my clinical question and whether
or not they included patient oriented outcomes. One article was published in 2012 and the other
two articles were published in 2011. All studies selected had very similar inclusion and exclusion
criteria. Inclusion criteria included that the study was randomized, controlled, double blind and
peer reviewed. Patients had to have had the diagnosis of hypoparathyroidism for at least a year
and were currently on stable calcium and vitamin D supplements. Exclusion criteria included
patients who had certain medication use within the timeframe of the diagnosis of
hypoparathyroidism. The summary of the statistics that were utilized and reported were the mean
change from baseline, relative benefit increase (RBI), absolute benefit increase (ABI), and the
numbers needed to treat (NNT). Table 1 displays the demographics and characteristics of the
included studies in this systematic review.
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Table 1: Demographics & Characteristics of Included Studies.
Study

Type

#
Pts

Age Inclusion Criteria
(yrs)

Exclusion
Criteria

W/
D

Interventions

Cusano1
(2013)

Prospective
cohort

82

25 68

2 yrs
hypoparathyroidism
diagnosis
Stable regimens of
supplemental Ca
and vitamin D for
at least 6 mo.

55

PTH (I-84)
subcutaneous
injections
every day for
2 years

Sikjaer6
(2011)

Randomized
control trial

62

31 78

Plasma ionized Ca
and Mg levels w/in
normal ranges
Pts with regular use
of vat. D
supplements for a
minimum of 3
months prior to the
study
Women on childbearing age if they
did not plan
pregnancy and/or
report use of
contraception

5

PTH (I-84)
subcutaneous
injections
every day for
6 months

Winer7
(2012)

Randomized
crossover
trial

8

36 54

Diagnosis of
postsurgical
hypoparathyroidism
x 12 months
Received calcitrol
and Ca supplements

Bisphosphonate
use w/in 5 years
or more than 6
months at a
time
Women w/ 5
years’
menopause
Pts who were
on HRT,
SERMs,
corticosteroids,
fluoride, Li,
statin, loops, or
MTX.
Severely
impaired renal
patients
Impaired
hepatic function
Pts dx with
alcoholism or
chronic drug
use, malignant
disease,
sarcoidosis,
Paget disease.
SERM use,
corticosteroids,
fluoride, Li, and
anticonvulsants
Not included in
study

0

PTH (I-34)
delivered by
insulin pump
for 6 months
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OUTCOMES MEASURED
The outcomes measured in this study were based on the number of patients who were
able to eliminate supplemental calcium from the diet. Other outcomes included were the least
amount of PTH required to maintain therapeutic serum calcium levels, the method of PTH
delivery (subcutaneous injections vs continuous infusion pump), and the number of patients who
were able to reduce the amount of supplemental calcium from their diet. These outcomes were
measured using serum calcium and vitamin D levels, urine calcium levels, and the amount of
PTH necessary for delivery.
RESULTS
In the prospective cohort study Cusano et al. 82 patients were treated with PTH (1-84) for
four years, with continuous monitoring of calcium and vitamin D requirements, serum urinary
calcium, serum phosphorus, bone turnover markers, and bone mineral density (BMD)1. The
patients selected were based on the set of inclusion and exclusion criteria as provided in Table 1.
Of the 82 patients who provided written informed consent to participate in the study, only 27
patients were followed for the duration of the study and were included in the analysis of data1.
The most common reason for loss to follow up was logistics of travel and loss to follow up. The
demographics of the study included patients between the ages of 25 – 68 years with a mean age
of 51 years, and 74% were women. The two major etiologies of hypoparathyroidism were
postsurgical and autoimmune disease1. Patients were administered PTH (1-84) at a starting dose
of 100 mcg subcutaneously every other day. Monitoring was accomplished by a review of
symptomatology and regular measurements of serum and urine calcium levels1. The levels were
monitored at baseline three times before treatment and at months 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 30,
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36, 42, and 481. The primary outcome measured was if whether or not patients could have their
dose of supplemental calcium and vitamin D requirements reduced or completely eliminated
from their diet. The data reported was continuous and could not be converted into dichotomous
data. Table 2 summarizes the data presented in the Cusano et al. study.
Table 2: Median change of supplemental calcium from baseline
Supplemental Calcium
Requirements
P = 0.006

Baseline
2.7 +/- 3 grams per day

4 years of PTH therapy
1.7 +/- 3 grams per day

This study demonstrates that after four years, the patients who received the PTH
replacement therapy were able to significantly reduce or completely eliminate their daily calcium
and vitamin D supplements from their diet. The p value is reported at 0.006 which is statistically
significant, meaning that the intervention of PTH replacement therapy was proven to be effective
in this study. Throughout the study, there were 11 episodes of mild hypercalcemia in eight
subjects with the majority of episodes occurring within the first 6 months and resolving with
adjustment of supplemental calcium and vitamin D. No episodes required hospitalizations. The
most common adverse reactions reported from patients were musculoskeletal, gastrointestinal,
and mental and mood.
In the randomized crossover trial Sikjaer et al. 62 patients with the diagnosis of
hypoparathyroidism were randomized to daily treatment with PTH (1-84) or similar placebo for
24 weeks as add-on therapy to conventional treatment6. The patients were selected based on a set
of inclusion and exclusion criteria as outlined in Table 1. A total of 5 patients did not complete
the trial – one patient never started the treatment, two patients dropped out for personal reasons,
and two patients dropped out as a result of side effects (one reporting nausea and one reporting
dizziness)6. The only statistically significant adverse reaction of PTH replacement therapy
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compared with the placebo group was reported to be nausea (p < 0.001)6. The demographics of
the study included patients between the ages of 31 and 78 years of age with a mean age of 52
years, and 86% were females. The major etiology of hypoparathyroidism was postsurgical (94%
of patients in the study). Patients were randomly assigned to receive a daily self-administered
subcutaneous injection of either 100 mcg of PTH (1-84) or placebo. According to a predefined
schedule, daily doses of vitamin D and calcium supplements were titrated down if patients
developed hypercalcemia (plasma ca+2 > 1.40 mmol/L). Patients were monitored with office
visits, fasting blood samples, and 24-hour urine samples at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and
24. The primary outcome measured was whether or not patients could completely eliminate the
need for supplemental calcium and vitamin D from their diet. The data was reported in
dichotomous form. The data was analyzed in the groups to which they were randomized
(intention to treat analysis), with less than 5% of the data missing. Tables 3, 4, and 5 summarize
the results of the Sikjaer et al. study.
Table 3: Number of patients able to discontinue supplemental calcium intake
PTH (n = 32)
15

Number of patients

Placebo (n=30)
0

Table 4: Efficacy of PTH replacement therapy in eliminating supplemental calcium from diet
Proportion of
patients
eliminating
supplemental
calcium on
placebo
(CER)
0
P < 0.001

Proportion of
patients
eliminating
supplemental
calcium on PTH
(EER)

Relative benefit
increase (RBI)
EER- CER
CER

Absolute benefit
increase (ABI)
EER - CER

Number needed
to treat (NNT)
1/ABI

0.469

0

0.469

3
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Table 5: Efficacy of PTH replacement therapy on development of adverse events
Proportion of
patients
experiencing
nausea on
placebo
(CER)
0
P <0.001

Proportion of
patients
experiencing
nausea on PTH
(EER)
0.25

Relative risk
increase (RRI)
EER- CER
CER
0

Absolute risk
increase (ARI)
EER - CER

Number needed
to harm (NNH)
1/ARI

0.25

4

This study demonstrates that PTH replacement therapy may eliminate the need for
supplemental calcium and could be a cost-effective treatment option for patients with
hypoparathyroidism. The ABI displays an increase in treatment effect with the PTH group
compared with the placebo group. The RBI displays the effectiveness of PTH replacement
therapy compared with the probability of eliminating supplemental calcium from the diet without
the therapy. The NNT is calculated to determine the number of patients that need to receive PTH
replacement therapy in order to reduce the need of supplemental calcium from the diet. In the
Sikjaer et al. study, only three patients require treatment to have one completely eliminate
supplemental calcium from the diet. The NNH was calculated to determine the number of
patients that need PTH replacement therapy in order to experience nausea. Four patients require
treatment to have one experience nausea as a side effect of PTH replacement therapy compared
to the control group.
In the randomized crossover trial conducted by Winer et al. 8 patients with the diagnosis
of hypoparathyroidism were used to compare continuous PTH (1-34) delivery, by insulin pump,
with twice-daily subcutaneous injections. They compared the amount necessary to ensure safe
and effective management of calcium levels in the serum, and whether or not subcutaneous
delivery of PTH could be used as an alternative to twice-daily injections. The patients were
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selected based on a set of inclusion and exclusion criteria as stated in Table 1. All patients
selected completed the trial. The demographics of the patients selected to participate had
received a diagnosis of postsurgical hypoparathyroidism for at least 12 months. The mean age
was 46 years, with a range of 36 – 54 years of age. Patients were randomly assigned, at study
entry in blocks of four to receive PTH (1-34) initially either by insulin pump or by twice-daily
injection and were crossed over to the alternate delivery method after the initial 3-month
treatment evaluation7. Patients were monitored at 0, 3, and 6 months throughout the study via
four-day inpatient admissions. During these admissions, PTH therapy by pump or injections was
initiated and dose adjusted before discharge. Subjects were instructed not to alter activity level
throughout the study, and completed weekly questionnaires, via the study website, that screen for
symptoms of hypoparathyroidism or adverse events. The primary outcome measured was the
amount of PTH (1-34) required for adequate management of patients with hypoparathyroidism.
The data was presented in dichotomous form. The data was analyzed in the groups to which they
were randomized (intention to treat analysis), and then crossed over. Table 6 summarizes the
results of the Winer et al. study.
Table 6: Median change of PTH (1-34) required from baseline
Amount of PTH

Twice-daily injections
37 +/- 14 mcg per day

Insulin pump delivery
13 +/- 4 mcg per day

P < 0.001
Winer et al. demonstrates that if pump therapy is used to manage PTH delivery in
patients with hypoparathyroidism, then the amount of PTH required to minimize the
complications of hypoparathyroidism is less than using the subcutaneous injections of PTH. This
ultimately results in reducing the cost disparity with PTH replacement therapy7. No serious
adverse reactions occurred throughout the study. Two patients experiencing transient injection

Kelly, PTH Replacement Therapy 10
site erythema. At the end of the study, seven of the either patients preferred pump therapy over
twice-daily delivery due to greater convenience of use.
DISCUSSION
These three studies support the use of PTH replacement therapy as effective in the
management of patients with hypoparathyroidism. PTH replacement therapy is currently
approved as an adjunct treatment for management of patients with hypoparathyroidism. The only
condition in which PTH mono therapy is currently approved by the FDA is osteoporosis2.
Contraindications for PTH replacement therapy include the diagnosis of hyperparathyroidism,
hypercalcemia, or patients at a higher baseline risk for osteosarcoma2. Another absolute
contraindication for therapy also includes Paget disease of the bone, or any type of malignancy
as hypercalcemia may be a result of the natural course of the disease. Problems with PTH
therapy in the past include the development of osteosarcomas. PTH replacement therapy has
been studied in osteoporosis treatment and is proven to produce an accumulation of longer lived,
apoptosis-resistant osteoblasts on bone surfaces that result in the risk of an osteosarcoma2.
Limitations of searching for studies were due to the fact that PTH replacement therapy is
still new and not very well studied for the treatment of patients with hypoparathyroidism.
Another major limitation of these three studies were the small study size. In each study, the vast
majority of patients’ etiology of hypoparathyroidism was due to surgical resection of the thyroid
gland, therefore limiting data on those with autoimmune or genetic causes of
hypoparathyroidism. Also, the only study that proved to successfully proved to safely eliminate
the need of supplemental calcium and vitamin D from the diet was Sikjaer et al. Cusano et al.
proved that the amount of supplemental calcium and vitamin D can be significantly reduced
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while on PTH replacement therapy, while Winer et al proved that the delivery method can play a
role on cost of therapy and amount of PTH necessary for successful treatment.
CONCLUSION
Although further studies are warranted, the three studies strongly suggest that PTH
replacement therapy can be used as treatment for patients with hypoparathyroidism1,6,7. Each of
the studies followed the patients for an adequate amount of time although the sample sizes were
relatively small in each study. However, the results still strongly supported the notion of PTH
replacement therapy as being effective. Future study is warranted to determine whether or not
PTH replacement therapy can be used for patients with multiple etiologies (autoimmune,
genetic) of hypoparathyroidism. Study design could also be manipulated to determine whether or
not PTH replacement therapy could be used for patients who had a diagnosis of acute
hypoparathyroidism, as these studies only used patients who had a diagnosis of chronic
hypoparathyroidism. It would also be beneficial to know the long term side effects of PTH
replacement therapy as all three studies could not make a comment.
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